1. Stocks
  2. Pharming Group N.V. - ADR
  3. Swot
swot-logo

Pharming Group N.V. - ADR SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Pharming Group N.V. - ADR has 24 Strengths, 5 Weaknesses, 0 Opportunities and 2 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Add SWOT widget to your site/app

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Companies with 10% increase in share price over three months, with rising net profit growth

Strong Momentum: Price above short, medium and long term moving averages

Expensive Rockets (DVM)

Relative Outperformance versus Industry over 1 Month

Rising Net Cash Flow and Cash from Operating activity

Relative Outperformance versus Industry over the Quarter (3 Months)

Turnaround Companies: Loss to Profit QoQ

Weekly Strategy: High Momentum Score Stocks (subscription)

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Companies with reducing Debt

Stock gained more than 20% in one month

Book Value per share Improving for last 2 years

Top Gainers

Stock with Low PE (PE < = 10)

RSI indicating price strength

Negative to Positive growth in Sales and Profit with Strong Price momentum

Volume Shockers

Highest Recovery from 52 Week Low

Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Low Piotroski Score : Companies with weak financials

Annual net profit declining for last 2 years

Stocks rising sharply on very low month volumes

MFs decreased their shareholding last quarter